FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1519232637> ?p ?o ?g. }

• W1519232637 endingPage "424" @default.
• W1519232637 startingPage "415" @default.
• W1519232637 abstract "BACKGROUND Human epidermal growth factor receptor 2 (HER2) is a therapeutic target in patients with esophageal adenocarcinoma (EAC), with gene amplification used as a selection criterion for treatment, although to the authors' knowledge the concordance between amplification and HER2 protein expression remains undefined in EAC. Furthermore, the association between HER2 and its interacting partner, human epidermal growth factor receptor 3 (HER3), is unknown yet appears to be of potential therapeutic relevance. METHODS Patients with untreated EACs (N = 673) were analyzed for HER2 amplification and polysomy 17 by fluorescence in situ hybridization in parallel with immunohistochemistry (IHC) (IHC scores of 0-1+, 2+, and 3+). Amplification was defined as HER2/CEP17 ≥ 2. HER3 expression by IHC was analyzed in randomly selected cases (n = 224). IHC and fluorescence in situ hybridization results were compared using least squares linear regression. RESULTS Overall, 17% of the EACs (116 of 673 EACs) were HER2-amplified with an amplification frequency that was highest among IHC3+ cases (89%) and declined among IHC2+ cases (13%) and IHC0 to IHC1+ cases (4%). Among HER2-amplified cases, the level of amplification increased linearly with HER2 membranous expression (HER2/CEP17 ratio: 7.9 in IHC3+ and 5.5 in IHC2+ vs 2.8 in IHC0 to IHC1+ [P < .0001]), with 14% of amplified tumors demonstrating absent/faint expression (IHC0 to IHC1+). Polysomy 17 was not found to be associated with HER2 expression. Cytoplasmic HER3 expression was detected in 87% of tumors (195 of 224 tumors) and was found to be significantly associated with better differentiation (P < .0001). Stepwise increases in HER3 expression were associated with higher HER2 expression levels (P = .0019). CONCLUSIONS Levels of HER2 protein expression and amplification were found to be linearly associated and highly concordant. Among amplified tumors with absent/faint expression, the level of amplification was low. Frequent expression of HER3 suggests its relevance as a therapeutic target, and its significant association with HER2 supports ongoing efforts to inhibit HER2/HER3 in patients with EAC. Cancer 2014;120:415–424. © 2013 American Cancer Society." @default.
• W1519232637 created "2016-06-24" @default.
• W1519232637 creator A5002209179 @default.
• W1519232637 creator A5013749695 @default.
• W1519232637 creator A5045186065 @default.
• W1519232637 creator A5049291606 @default.
• W1519232637 creator A5060720802 @default.
• W1519232637 creator A5064038800 @default.
• W1519232637 creator A5069073626 @default.
• W1519232637 creator A5070740990 @default.
• W1519232637 creator A5075740509 @default.
• W1519232637 date "2013-10-21" @default.
• W1519232637 modified "2023-09-24" @default.
• W1519232637 title "<i>HER-2/neu</i>gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma" @default.
• W1519232637 cites W1606124548 @default.
• W1519232637 cites W1963858122 @default.
• W1519232637 cites W1987009448 @default.
• W1519232637 cites W1993804787 @default.
• W1519232637 cites W1999368908 @default.
• W1519232637 cites W2015918488 @default.
• W1519232637 cites W2036977598 @default.
• W1519232637 cites W2041560748 @default.
• W1519232637 cites W2042095374 @default.
• W1519232637 cites W2049095878 @default.
• W1519232637 cites W2054390556 @default.
• W1519232637 cites W2069526613 @default.
• W1519232637 cites W2078620068 @default.
• W1519232637 cites W2089071484 @default.
• W1519232637 cites W2100439220 @default.
• W1519232637 cites W2103908350 @default.
• W1519232637 cites W2104558660 @default.
• W1519232637 cites W2109491042 @default.
• W1519232637 cites W2110941212 @default.
• W1519232637 cites W2112426819 @default.
• W1519232637 cites W2112853929 @default.
• W1519232637 cites W2122113038 @default.
• W1519232637 cites W2130900820 @default.
• W1519232637 cites W2135990563 @default.
• W1519232637 cites W2138083541 @default.
• W1519232637 cites W2139444209 @default.
• W1519232637 cites W2151464858 @default.
• W1519232637 cites W2152163220 @default.
• W1519232637 cites W2152362765 @default.
• W1519232637 cites W2152494192 @default.
• W1519232637 cites W2153845297 @default.
• W1519232637 cites W2155275416 @default.
• W1519232637 cites W2165411051 @default.
• W1519232637 cites W3143872592 @default.
• W1519232637 cites W4376596982 @default.
• W1519232637 doi "https://doi.org/10.1002/cncr.28435" @default.
• W1519232637 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3932765" @default.
• W1519232637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24151090" @default.
• W1519232637 hasPublicationYear "2013" @default.
• W1519232637 type Work @default.
• W1519232637 sameAs 1519232637 @default.
• W1519232637 citedByCount "27" @default.
• W1519232637 countsByYear W15192326372014 @default.
• W1519232637 countsByYear W15192326372015 @default.
• W1519232637 countsByYear W15192326372016 @default.
• W1519232637 countsByYear W15192326372017 @default.
• W1519232637 countsByYear W15192326372018 @default.
• W1519232637 countsByYear W15192326372019 @default.
• W1519232637 countsByYear W15192326372020 @default.
• W1519232637 countsByYear W15192326372021 @default.
• W1519232637 countsByYear W15192326372022 @default.
• W1519232637 crossrefType "journal-article" @default.
• W1519232637 hasAuthorship W1519232637A5002209179 @default.
• W1519232637 hasAuthorship W1519232637A5013749695 @default.
• W1519232637 hasAuthorship W1519232637A5045186065 @default.
• W1519232637 hasAuthorship W1519232637A5049291606 @default.
• W1519232637 hasAuthorship W1519232637A5060720802 @default.
• W1519232637 hasAuthorship W1519232637A5064038800 @default.
• W1519232637 hasAuthorship W1519232637A5069073626 @default.
• W1519232637 hasAuthorship W1519232637A5070740990 @default.
• W1519232637 hasAuthorship W1519232637A5075740509 @default.
• W1519232637 hasBestOaLocation W15192326372 @default.
• W1519232637 hasConcept C104317684 @default.
• W1519232637 hasConcept C121608353 @default.
• W1519232637 hasConcept C126322002 @default.
• W1519232637 hasConcept C142724271 @default.
• W1519232637 hasConcept C143998085 @default.
• W1519232637 hasConcept C150194340 @default.
• W1519232637 hasConcept C153911025 @default.
• W1519232637 hasConcept C160798450 @default.
• W1519232637 hasConcept C204232928 @default.
• W1519232637 hasConcept C2777542201 @default.
• W1519232637 hasConcept C2781182431 @default.
• W1519232637 hasConcept C2781303241 @default.
• W1519232637 hasConcept C30481170 @default.
• W1519232637 hasConcept C502942594 @default.
• W1519232637 hasConcept C54355233 @default.
• W1519232637 hasConcept C71924100 @default.
• W1519232637 hasConcept C7602840 @default.
• W1519232637 hasConcept C81439078 @default.
• W1519232637 hasConcept C86803240 @default.
• W1519232637 hasConceptScore W1519232637C104317684 @default.
• W1519232637 hasConceptScore W1519232637C121608353 @default.
• W1519232637 hasConceptScore W1519232637C126322002 @default.

• next